* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download mps i
Survey
Document related concepts
Transcript
BIOCHEMICAL GENETICS Greg Enns, MB, ChB, FAAP Professor of Pediatrics Director, Biochemical Genetics Program Lucile Packard Children’s Hospital October 22, 2015 Learning Goals Develop abilities to recognize signs and symptoms associated with inborn errors of metabolism Become aware of clues to an underlying inborn error of metabolism by using simple lab tests 2 Lecture Outline Inborn Errors of Metabolism ◦ Signs and Symptoms ◦ Diagnostic Tests Routine labs Biochemical profiling So what exactly is a Biochemical Geneticist anyway? Inborn Errors of Metabolism “Metabolic Disorders” Inherited disorders of intermediary metabolism ◦ ◦ ◦ ◦ Autosomal recessive Autosomal dominant X-linked Maternal (mitochondrial) inheritance Metabolic imbalance most commonly secondary to an enzyme deficiency Toxic metabolites Deficiency states Altered energy production 5 Who, What, & How? Common presentations ◦ Neurologic decompensation ◦ Multi-organ system involvement ◦ Lysosomal storage disorders Types of tests ◦ Basic ◦ Complex ◦ Newborn screening Test interpretations ◦ Common mistakes ◦ Case examples 6 Who to Test Clinical Features Neurologic symptoms ◦ Cataracts ◦ Pigmentary retinopathy ◦ Altered Mental Status ◦ Developmental regression Mental retardation Psychiatric illness ◦ Autism? 7 Failure to thrive SIDS Non-immune hydrops Eye findings Hepatosplenomegaly Cardiomyopathy Bone/joint disease ◦ Contractures ◦ Dysostosis multiplex ◦ Osteonecrosis Unusual odor Signs and Symptoms of Inborn Errors of Metabolism Appear after an interval of good health (hours, days) in a usually previously healthy full-term infant Unmasked by “stressors” that lead to catabolism (e.g. infection, fasting, dehydration, excessive protein, birth) Non-specific (limited response to stress in neonates) 8 Signs and Symptoms of Inborn Errors of Metabolism Failure to thrive, feeding difficulties Respiratory distress Hypotonia, seizures, lethargy Hypothermia (especially neonates) 9 Signs and Symptoms of Inborn Errors of Metabolism ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ Ocular findings Hepatosplenomegaly Cardiomyopathy Renal tubular disease Abnormal odor Unusual skin, hair Dysostosis multiplex Dysmorphic features 10 Signs and Symptoms of Inborn Errors of Metabolism Typically patients who have metabolism disorders display a constellation of features Isolated failure to thrive, cardiomyopathy, etc. in the absence of other organ system involvement or other clinical features (e.g. developmental delay) would be unusual 11 Signs and Symptoms of Inborn Errors of Metabolism MAY PRESENT AT ANY AGE 12 Case #1 A 4-day-old boy is taken to the emergency room on Christmas eve because of poor feeding and lethargy. He is hypothermic and is tachypneic. He has elevated (3+) ketones in his urine and a metabolic acidosis (anion gap 25 with normal lactate). His ammonia is 735 M (normal 5-35). 13 Case #1 This presentation is most suggestive of …? A) Maple syrup urine disease B) Urea cycle defect C) Fatty acid oxidation defect D) Glycogen storage disease E) Organic acidemia 14 Your answer? E) Organic acidemia 15 THE ANION GAP + Na - [Cl + HCO3 ] 16 THE ANION GAP Total serum cations: Na + UC Total serum anions: Cl + HCO3 + UA So… NA + UC = UA + Cl + HCO3 17 THE ANION GAP UA – UC = Na+ - [Cl- + HCO3-] = the anion gap 18 Concentrations of “unmeasured” cations and anions(mEq/L) Unmeasured Anions Protein Unmeasured Cations 15 PO4 2 SO4 1 Organic acids 5 Total 19 23 K Ca Mg Total 4.5 5.0 1.5 11 Metabolic Acidosis with Increased Anion Gap Increased Unmeasured Anion: Methanol, metformin Uremia Diabetic ketoacidosis Paraldehyde, phenformin Inborn errors of metabolism Lactic acidemia Ethanol, ethylene glycol Salicylates, solvents, strychnine 20 Metabolic Acidosis with Increased Anion Gap Decreased Unmeasured Cation*: Hypokalemia Hypocalcemia Hypomagnesemia *Possible in theory, but rarely encountered 21 Metabolic Acidosis with Normal Anion Gap • • Renal tubular acidosis Intestinal loss of bicarbonate 22 Prototypical Metabolic Pathway Negative Feedback TA A EAB EBC A B F ECD C D G Cell membrane A, B, C, D – substrate and products of major pathway F, G – products of minor pathway T – transporter ; E - enzymes 23 The Laboratory specimen 24 results Organic Acids (GC-MS) 25 Urine only Qualitative screen 100’s of compounds 3 hour prep 30 min run Methylmalonic Acidemia Ion Abundance Total Ion Chromatogram Time (min) 26 Case #1 Initial methylmalonic acid (MMA) level 1,200 uM (nl <0.3 uM) Treated with: ◦ High dextrose intravenous fluids + insulin ◦ Intravenous “nitrogen scavenging” medications Sodium benzoate + sodium phenylacetate ◦ Intravenous carnitine ◦ Intramuscular hydroxocobalamin Dialysis is often needed to decrease MMA and ammonium levels, but avoided in this case 27 The Cobalamin Pathway TC II TC II OH-Cbl OH-Cbl TC II Methionine Synthase E,G Homocysteine Methionine OH-Cbl+3 Me Cbl F C,D +3 OH-Cbl Cbl+3 Cbl+2 A,H Cbl+1 B Ado Cbl L-Methylmalonyl Succinyl CoA Methylmalonyl CoA CoA Mutase 28 Methylmalonic Acidemia Common signs/symptoms: ◦ ◦ ◦ ◦ ◦ ◦ lethargy intermittent vomiting dehydration failure to thrive respiratory distress hypotonia Matsui et al. NEJM 308:857, 1983 29 30 BRAIN INJURY IN ORGANIC ACIDEMIAS delayed myelination caudate and putamen hyperintensity Pediatr Res 40:404-9, 1996 31 Case #2 You are called about a 55-year-old male who became confused and lethargic a few days after endoscopic sinus surgery to remove nasal polyps that were causing chronic sinusitis. He had been discharged home on steroids to prevent swelling. His wife took him to the emergency room after he became more confused and disoriented. He progressed to a coma and was placed on mechanical ventilation in the intensive care unit. 32 Case #2 The ICU physician upon reviewing the initial laboratory studies noted a respiratory alkalosis and normal complete blood count, glucose, and liver enzymes. Cerebrospinal fluid studies and urinalysis are normal. Blood, urine, and cerebrospinal fluid cultures are obtained. A urine toxicology screen was also normal. Initial head CT scan and CXR were normal. 33 Case #2 Your differential diagnosis includes which of the following? A) Steroid psychosis B) Occult infection C) Intoxication D) Inborn error of metabolism E) All of the above 34 Your answer? E) All of the above 35 Case #2 Although most metabolic studies take days to weeks to obtain results, you recall that ammonia is a central respiratory stimulant and urea cycle disorders often are associated with tachypnea. Moreover, unlike many metabolic disorders, a metabolic acidosis is typically not present initially in urea cycle disorders. You look at the lab results again and notice the blood urea nitrogen is low. 36 Case #2 So…you check an ammonia (obtained on ice and sent to the lab quickly) and find an abnormal elevation. The ammonia level is 281 M (normal 5-35). 37 Case #2 The most likely diagnosis is: A) Urea cycle disorder B) Mitochondrial disease C) Propionic acidemia D) Medium-chain acyl-CoA dehydrogenase deficiency E) Proteus mirabilis urinary tract infection 38 Your diagnosis? A) Urea cycle disorder 39 Quantitative Amino Acids (HPLC) Plasma, urine, CSF 40 amino acids (sometimes more) 10 minute prep 3 hour run per sample 40 41 Case #2 Metabolic labs: glutamine citrulline 3 uM (8-47) orotic acid <1 g/mg creatinine (<4.7) 42 43 Urea Cycle Disorders Clinical Features ◦ Term birth ◦ ~DOL 2 poor feeding, vomiting, lethargy progressing to coma, apnea ◦ Seizures may occur with cerebral edema ◦ Often mistaken for sepsis ◦ Later onset with ataxia, altered mental status (postpartum) 44 Late-Onset Urea Cycle Disorders Behavioral problems ◦ ◦ ◦ ◦ Agitation Delirium Aggression Confusion Ataxia Headache Hemiparesis Nassogne et al. JIMD 28:407-14, 452005 Lysosomal Storage Disorders Family of > 40 disorders; collective prevalence ~1:8,0001 Enzyme deficiency causes lysosomes to become engorged1 Each disease is a consequence of type of substrate and where it accumulates1 Progressive accumulation of substrate may result in irreversible damage2 1. Meikle P et al. JAMA. 1999;281:249-254. 2. Wraith JE et al. J Pediatr. 2004;144:581-588. 46 MPS ENZYME BLOCKS COOH S-O O COOH O-S iduronate sulfatase COOH 47 O O O NAc NAc HUNTER (MPS II) S-O COOH S-O O O NAc -L-iduronidase S-O HURLER (MPS I) O O NAc Lysosomal Storage Disorders Normal Cell Abnormal Cell 48 CNS Involvement Significant or severe CNS involvement (~ 54%) Mucolipidosis type II / III 2% Niemann-Pick A 2% GM 1 Gangliosidosis 2% No or minimal CNS involvement (~ 46%) Sandhoff 2% Niemann-Pick C 4% Gaucher type I 13% Other 2% Scheie (MPS I) 1% Hurler/Scheie (MPS I) 4% Sanfilippo B 4% Fabry 7% Tay-Sachs 4% Hunter Mild 1% Krabbe 6% Pompe 5% Hunter Severe 5% Sanfilippo A 7% Morquio 5% Metachromatic Leukodystrophy 8% Adapted from Meikle P et al. JAMA. 1999;281:249-254. Hurler (MPS I) 4% Cystinosis 4% Sanfilippo D 1% -Mannosidosis 1% Gaucher type 2 & 3 1% Niemann-Pick B 2% Maroteaux-Lamy 3% 49 Mucopolysaccharidosis type I Pathology -L-iduronidase enzyme deficiency Accumulation of glycosaminoglycans (GAGs) Onset Severe form: first 6 months after birth Attenuated form: 3 to 8 years of age Progression Often life threatening Severe cases life span < 10 y Attenuated cases life span ≈ normal 50 1. Meikle P et al. JAMA. 1999;281:249-254. Inheritance Autosomal Recessive Prevalence ≈1:90,0001 Disease-ata-Glance Signs & Symptoms Look for unusual symptoms or clusters of more common symptoms MPS I Macrocephaly Developmental delay Chronic rhinitis/otitis Obstructive airway disease Umbilical/inguinal hernia Skeletal deformities Carpal tunnel syndrome Corneal clouding Hearing loss Enlarged tongue Cardiovascular disease Hepatosplenomegaly Joint stiffness Neufeld EF, Muenzer J. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3421-3452. 51 Disease Progression: Severe MPS I 10 months 12 months 39 months 22 months 34 months 52 Disease Progression: Mild MPS I 3 years 4 years 11 years 6 years 8 years 53 MPS I Clinical Heterogeneity Attenuated “Scheie” MPS I S Severe “Hurler-Scheie” MPS I HS “Hurler” MPS IH Courtesy of Emil Kakkis, MD. All patients typically have < 1% of normal enzyme levels, but only MPS l H involves the CNS 54 Peripheral Nervous System Involvement • Carpal tunnel syndrome – nerve entrapments/ nerve compressions • Most patients lack typical symptoms until severe compression occurs 55 Contractures of the Arm 56 Skeletal Abnormalities 57 (Clarke LA, 1997) Photo reproduced by permission of Hodder/Arnold Publishers. Gibbus in MPS I 58 Dimethylmethylene Blue Binding Assay For Glycosaminoglycans Urine + DMB reagent Blue product Blank 5 µg/ml 17.5 µg/ml 35 µg/ml 50 µg/ml Courtesy T. Cowan Thin-layer chromatography Normal MPS I Hurler MPS I Scheie Dermatan, Heparan Dermatan, Heparan MPS II Hunter Dermatan, Heparan MPS III Sanfilippo MPS IV Morquio MPS VI MaroteauxLamy Heparan Keratan Dermatan MPS VII Sly Dermatan, Heparan Courtesy of T. Cowan 60 SUMMARY High index of suspicion – consider IEM in parallel with more common conditions Presentations are non-specific Simple screening tests yield critical diagnostic clues 61 Metabolic Disease Treatment Team Primary Care Physician Ophthalmologist Surgeon Otorhinolaryngologist Pulmonologist Interventional Geneticist Cardiologist Hematologist Orthopedist Nephrologist Neurologist Dentist Palliative Care Specialist 62 Anesthesiologist Gastroenterologist Genetic Counselor